Fei Yuan, Maomao Liu, Yunfeng Yan, Nan Liu, Shuzheng Lyu
{"title":"Reperfusion for Proximal Left Circumflex Artery Chronic Total Occlusion Benefits Patients With Diabetes: A Retrospective Cohort Study.","authors":"Fei Yuan, Maomao Liu, Yunfeng Yan, Nan Liu, Shuzheng Lyu","doi":"10.1177/00033197251377325","DOIUrl":null,"url":null,"abstract":"<p><p>Diabetes with chronic total arterial occlusion carries a poor prognosis. Little is known about patients with diabetes and stable left circumflex artery (LCX) chronic total occlusion (LCX-CTO). We aimed to determine whether stable LCX-CTO should be recanalized in patients with diabetes. We analyzed patients with LCX-CTO, diabetes, and stable clinical symptoms (i.e., silent ischemia or symptomatic stable angina), who underwent successful revascularization (SR) or medical therapy (MT). The primary endpoint was major adverse cardiac events. Propensity score-matched analyses and Cox regression were performed. The proximal LCX-CTO subpopulation was analyzed. A stratified subgroup analysis was conducted for the primary endpoint. We enrolled 620 patients, stratified into MT (448, 72.26%) and SR groups (172, 27.74%). After a median 44-month follow-up, univariate and multivariable models showed that SR offered no clinical benefits regarding major adverse cardiac events (adjusted hazard ratio [aHR]: 0.860, 95% confidence interval [CI]: 0.520-1.423, <i>P</i> = .558). This was consistent for other clinical endpoints as well. However, in the subpopulation with proximal LCX-CTO, SR was superior in terms of cardiac (aHR: 0.284, 95% CI: 0.082-0.984) and all-cause mortality (aHR: 0.455, 95% CI: 0.167-1.239). Revascularization should be attempted in patients with diabetes who have proximal LCX-CTO.</p>","PeriodicalId":8264,"journal":{"name":"Angiology","volume":" ","pages":"988-998"},"PeriodicalIF":2.7000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00033197251377325","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
引用次数: 0
Abstract
Diabetes with chronic total arterial occlusion carries a poor prognosis. Little is known about patients with diabetes and stable left circumflex artery (LCX) chronic total occlusion (LCX-CTO). We aimed to determine whether stable LCX-CTO should be recanalized in patients with diabetes. We analyzed patients with LCX-CTO, diabetes, and stable clinical symptoms (i.e., silent ischemia or symptomatic stable angina), who underwent successful revascularization (SR) or medical therapy (MT). The primary endpoint was major adverse cardiac events. Propensity score-matched analyses and Cox regression were performed. The proximal LCX-CTO subpopulation was analyzed. A stratified subgroup analysis was conducted for the primary endpoint. We enrolled 620 patients, stratified into MT (448, 72.26%) and SR groups (172, 27.74%). After a median 44-month follow-up, univariate and multivariable models showed that SR offered no clinical benefits regarding major adverse cardiac events (adjusted hazard ratio [aHR]: 0.860, 95% confidence interval [CI]: 0.520-1.423, P = .558). This was consistent for other clinical endpoints as well. However, in the subpopulation with proximal LCX-CTO, SR was superior in terms of cardiac (aHR: 0.284, 95% CI: 0.082-0.984) and all-cause mortality (aHR: 0.455, 95% CI: 0.167-1.239). Revascularization should be attempted in patients with diabetes who have proximal LCX-CTO.
期刊介绍:
A presentation of original, peer-reviewed original articles, review and case reports relative to all phases of all vascular diseases, Angiology (ANG) offers more than a typical cardiology journal. With approximately 1000 pages per year covering diagnostic methods, therapeutic approaches, and clinical and laboratory research, ANG is among the most informative publications in the field of peripheral vascular and cardiovascular diseases. This journal is a member of the Committee on Publication Ethics (COPE). Average time from submission to first decision: 13 days